Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy - PubMed
3 hours ago
- #GLP-1 agonists
- #Incretin therapy
- #Metabolic disorders
- Incretin-based therapies have evolved from DPP-4 inhibitors to advanced GLP-1 receptor agonists (GLP-1RAs), and then to dual and triple agonists.
- GLP-1RAs like liraglutide and semaglutide provide significant weight loss and cardiometabolic protection.
- Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide show unprecedented efficacy, with up to 24% body weight reduction and improvements in hepatic and inflammatory markers.
- New agents like cotadutide and efinopegdutide expand treatment indications to metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).
- Despite promising outcomes, challenges include cost, accessibility, underrepresentation of low- and middle-income countries in trials, and pharmacogenomic variability influencing therapeutic response.
- Incretin-based multi-agonists offer a transformative, multi-system approach to metabolic disease, requiring tailored implementation and highlighting priorities for future research and equitable global integration.